Proteolytic Cleavage of Bioactive Peptides and Protease-Activated Receptors in Acute and Post-Colitis

The protease activity in inflammatory bowel disease (IBD) and irritable bowel syndrome has been studied extensively using synthetic fluorogenic substrates targeting specific sets of proteases. We explored activities in colonic tissue from a 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis rat model by investigating the cleavage of bioactive peptides. Pure trypsin- and elastase-like proteases on the one hand and colonic tissue from rats with TNBS-induced colitis in the acute or post-inflammatory phase on the other, were incubated with relevant peptides to identify their cleavage pattern by mass spectrometry. An increased cleavage of several peptides was observed in the colon from acute colitis rats. The tethered ligand (TL) sequences of peptides mimicking the N-terminus of protease-activated receptors (PAR) 1 and 4 were significantly unmasked by acute colitis samples and these cleavages were positively correlated with thrombin activity. Increased cleavage of β-endorphin and disarming of the TL-sequence of the PAR3-based peptide were observed in acute colitis and linked to chymotrypsin-like activity. Increased processing of the enkephalins points to the involvement of proteases with specificities different from trypsin- or chymotrypsin-like enzymes. In conclusion, our results suggest thrombin, chymotrypsin-like proteases and a set of proteases with different specificities as potential therapeutic targets in IBD.

[1]  A. Lambeir,et al.  The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model , 2021, Frontiers in Pharmacology.

[2]  I. De Meester,et al.  Local Colonic Administration of a Serine Protease Inhibitor Improves Post-Inflammatory Visceral Hypersensitivity in Rats , 2021, Pharmaceutics.

[3]  D. McKay,et al.  Epithelial production of elastase is increased in inflammatory bowel disease and causes mucosal inflammation , 2021, Mucosal Immunology.

[4]  J. Wallace,et al.  Increased Mucosal Thrombin is Associated with Crohn’s Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation , 2020, Journal of Crohn's & colitis.

[5]  A. Gargouri,et al.  Fecal Serine Protease Profiling in Inflammatory Bowel Diseases , 2020, Frontiers in Cellular and Infection Microbiology.

[6]  F. Barreau,et al.  Protease-Activated Receptors in the Intestine: Focus on Inflammation and Cancer , 2019, Front. Endocrinol..

[7]  W. Shih,et al.  µ‐opioid receptor, β‐endorphin, and cannabinoid receptor‐2 are increased in the colonic mucosa of irritable bowel syndrome patients , 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[8]  G. Farrugia,et al.  Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS , 2019, Gut.

[9]  J. Fichna,et al.  The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome. , 2019, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[10]  J. Fichna,et al.  Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[11]  F. Russo,et al.  Adipose Tissue-Derived Biomarkers of Intestinal Barrier Functions for the Characterization of Diarrhoea-Predominant IBS , 2018, Disease markers.

[12]  Å. Keita,et al.  Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitis , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[13]  O. Schilling,et al.  Specificity profiling of human trypsin-isoenzymes , 2018, Biological chemistry.

[14]  A. Lambeir,et al.  Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post‐inflammatory rat model for irritable bowel syndrome , 2018, British journal of pharmacology.

[15]  G. Barbara,et al.  Protease-activated receptor 1 is implicated in irritable bowel syndrome mediators–induced signaling to thoracic human sensory neurons , 2018, Pain.

[16]  J. Fichna,et al.  Antinociceptive potency of enkephalins and enkephalinase inhibitors in the mouse model of colorectal distension—proof‐of‐concept , 2018, Chemical biology & drug design.

[17]  M. Hollenberg,et al.  Functional Proteomic Profiling of Secreted Serine Proteases in Health and Inflammatory Bowel Disease , 2018, Scientific Reports.

[18]  L. Hellman,et al.  Extended cleavage specificity of human neutrophil cathepsin G: A low activity protease with dual chymase and tryptase-type specificities , 2018, PloS one.

[19]  B. Kuster,et al.  Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients , 2018, PloS one.

[20]  E. Mayer,et al.  Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome. , 2017, Gastroenterology.

[21]  M. Jiang,et al.  Unconjugated bilirubin ameliorates the inflammation and digestive protease increase in TNBS-induced colitis , 2017, Molecular medicine reports.

[22]  P. Sutton,et al.  Protease-activated Receptor 1 Plays a Proinflammatory Role in Colitis by Promoting Th17-related Immunity , 2017, Inflammatory bowel diseases.

[23]  Y. Taché,et al.  Epithelial expression and function of trypsin-3 in irritable bowel syndrome , 2017, Gut.

[24]  A. Lambeir,et al.  Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases , 2016, World journal of gastroenterology.

[25]  J. Timmermans,et al.  P2X3 Receptors Mediate Visceral Hypersensitivity during Acute Chemically-Induced Colitis and in the Post-Inflammatory Phase via Different Mechanisms of Sensitization , 2015, PloS one.

[26]  W. Henderson,et al.  Altered vasoactive intestinal peptides expression in irritable bowel syndrome patients and rats with trinitrobenzene sulfonic acid-induced colitis. , 2015, World journal of gastroenterology.

[27]  N. Bunnett,et al.  Corrigendum: Biased Signaling of Protease-Activated Receptors , 2015, Front. Endocrinol..

[28]  N. Bunnett,et al.  Biased Signaling of Protease-Activated Receptors , 2014, Front. Endocrinol..

[29]  N. Ruyssers,et al.  Histamine H4 and H1 receptors contribute to postinflammatory visceral hypersensitivity , 2014, Gut.

[30]  N. Cenac Protease-activated receptors as therapeutic targets in visceral pain. , 2013, Current neuropharmacology.

[31]  S. Hua,et al.  Targeting peripheral opioid receptors to promote analgesic and anti-inflammatory actions , 2013, Front. Pharmacol..

[32]  John E. Murphy,et al.  Global Substrate Profiling of Proteases in Human Neutrophil Extracellular Traps Reveals Consensus Motif Predominantly Contributed by Elastase , 2013, PloS one.

[33]  K. Garsed,et al.  Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit , 2013, Gut.

[34]  H. Lee,et al.  Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea , 2013, Scandinavian journal of gastroenterology.

[35]  Alma L Burlingame,et al.  Global identification of peptidase specificity by multiplex substrate profiling , 2012, Nature Methods.

[36]  P. N. Shaw,et al.  Study of beta endorphin metabolism in inflamed tissue, serum and trypsin solution by liquid chromatography–tandem mass spectrometric analysis , 2012, Analytical and Bioanalytical Chemistry.

[37]  L. Fricker,et al.  Substrate Specificity of Human Carboxypeptidase A6* , 2010, The Journal of Biological Chemistry.

[38]  F. Avilés,et al.  Characterization of the Substrate Specificity of Human Carboxypeptidase A4 and Implications for a Role in Extracellular Peptide Processing* , 2010, The Journal of Biological Chemistry.

[39]  L. Blackshaw,et al.  TRP channels: new targets for visceral pain , 2009, Gut.

[40]  R. Langer,et al.  Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. , 2009, Gastroenterology.

[41]  T. Wittmann,et al.  Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice , 2009, PAIN®.

[42]  T. Wittmann,et al.  Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. , 2009, The American journal of pathology.

[43]  J. Sung,et al.  Unbalanced expression of protease-activated receptors-1 and -2 in the colon of diarrhea-predominant irritable bowel syndrome patients , 2009, Journal of Gastroenterology.

[44]  H. Koistinen,et al.  Nexin-1 inhibits the activity of human brain trypsin , 2009, Neuroscience.

[45]  N. Vergnolle Proteinase-activated receptors (PARs) in infection and inflammation in the gut. , 2008, The international journal of biochemistry & cell biology.

[46]  Martin Strohalm,et al.  mMass data miner: an open source alternative for mass spectrometric data analysis. , 2008, Rapid communications in mass spectrometry : RCM.

[47]  S. Muhtaroğlu,et al.  Ameliorative effects of bombesin and neurotensin on trinitrobenzene sulphonic acid-induced colitis, oxidative damage and apoptosis in rats. , 2008, World journal of gastroenterology.

[48]  T. Wittmann,et al.  Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity , 2008, Gut.

[49]  M. Hollenberg,et al.  Trypsin IV or Mesotrypsin and p23 Cleave Protease-activated Receptors 1 and 2 to Induce Inflammation and Hyperalgesia* , 2007, Journal of Biological Chemistry.

[50]  F. Nagy,et al.  A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[51]  M. Steinhoff,et al.  Role for protease activity in visceral pain in irritable bowel syndrome. , 2007, The Journal of clinical investigation.

[52]  S. Collins,et al.  Visceral pain perception is determined by the duration of colitis and associated neuropeptide expression in the mouse , 2006, Gut.

[53]  G. Rogler,et al.  Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo , 2006, Clinical and experimental immunology.

[54]  N. Vergnolle,et al.  CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT , 2005, Gut.

[55]  P. Brun,et al.  Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[56]  G. Rogler,et al.  Cathepsin D is up‐regulated in inflammatory bowel disease macrophages , 2004, Clinical and experimental immunology.

[57]  G. Sanger Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain , 2004, British journal of pharmacology.

[58]  D. Santini,et al.  Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. , 2004, Gastroenterology.

[59]  J. Schwartz,et al.  Cell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysin. , 2002, The Biochemical journal.

[60]  A. van Dorsselaer,et al.  Proteolysis of the exodomain of recombinant protease-activated receptors: prediction of receptor activation or inactivation by MALDI mass spectrometry. , 2000, Biochemistry.

[61]  C. Craik,et al.  Cathepsin G Activates Protease-activated Receptor-4 in Human Platelets* , 2000, The Journal of Biological Chemistry.

[62]  W. Falk,et al.  Strictures in Crohn’s disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin , 1999, Gut.

[63]  R. Carraway,et al.  Neurotensin is a proinflammatory neuropeptide in colonic inflammation. , 1999, The Journal of clinical investigation.

[64]  J. Otlewski,et al.  Specificity of human cathepsin G. , 1998, Biochimica et biophysica acta.

[65]  L. Hersh,et al.  Identification of γ-Endorphin-Generating Enzyme as Insulin-Degrading Enzyme† , 1996 .

[66]  J. Bai,et al.  The Presence of Insulin‐degrading Enzyme in Human Ileal and Colonic Mucosal Cells , 1996, The Journal of pharmacy and pharmacology.

[67]  H. Nagura,et al.  Abnormal neuropeptide concentration in rectal mucosa of patients with inflammatory bowel disease , 1996, Journal of Gastroenterology.

[68]  T. Kageyama,et al.  Processing of the Precursors to Neurotensin and Other Bioactive Peptides by Cathepsin E (*) , 1995, The Journal of Biological Chemistry.

[69]  H. Nagura,et al.  Changes in neuropeptide‐containing nerves in human colonic mucosa with inflammatory bowel disease , 1994, Pathology international.

[70]  C. Surrenti,et al.  Colonic vasoactive intestinal polypeptide in ulcerative colitis , 1993, Journal of Physiology-Paris.

[71]  H. Singh,et al.  Dipeptidyl peptidase I from goat brain: Purification, characterization and its action on leu-enkephalin , 1993, Neurochemistry International.

[72]  C. Maison,et al.  Proteolysis of C3 on U937 cell plasma membranes. Purification of cathepsin G. , 1991, Journal of immunology.

[73]  T. Tanaka,et al.  Human leukocyte cathepsin G. Subsite mapping with 4-nitroanilides, chemical modification, and effect of possible cofactors. , 1985, Biochemistry.

[74]  H. Kern,et al.  Hormonal stimulation in the exocrine pancreas results in coordinate and anticoordinate regulation of protein synthesis , 1984, The Journal of cell biology.

[75]  C. O'Morain,et al.  Vasoactive intestinal peptide concentrations and immunocytochemical studies in rectal biopsies from patients with inflammatory bowel disease. , 1984, Gut.

[76]  S. Hamilton,et al.  Abnormalities of vasoactive intestinal polypeptide-containing nerves in Crohn's disease , 1980 .

[77]  J. Powers,et al.  Specificity of porcine pancreatic elastase, human leukocyte elastase and cathepsin G. Inhibition with peptide chloromethyl ketones. , 1977, Biochimica et biophysica acta.

[78]  J. Sallenave,et al.  Overexpression of Elastin Affects the Protease to Anti-Protease Balance and Protects Mice from Colitis , 2019 .

[79]  B. Korkmaz,et al.  Elastase-2/Leukocyte Elastase , 2013 .

[80]  H. Koistinen,et al.  Article in press-uncorrected proof Identification of novel peptide inhibitors for human trypsins , 2010 .

[81]  N. Talley Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity , 2009 .

[82]  D. Schomburg,et al.  Pancreatic elastase II , 1998 .

[83]  A. Blackburn Neurotensin. , 1978, Journal of clinical pathology. Supplement.